Researchers have delineated that non-hallucinogenic psychedelic analogs like tabernanthalog (TBG) induce neuroplasticity through the same receptor pathways as classical psychedelics (5-MeO-DMT) but without triggering immediate early gene activation linked to hallucinations. Published in Nature Neuroscience, this study elucidates mechanisms underpinning therapeutic benefits of these compounds, highlighting potential for targeted neuropsychiatric and neurodegenerative treatments with fewer side effects. This advancement paves the way for next-generation psychoplastogens that retain efficacy without hallucinogenic properties.